Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

• Payton A.-B. Weidenbacher,
• Mrinmoy Sanyal,
• Natalia Friedland,
• Shaogeng Tang,
• Prabhu S. Arunachalam,
• Mengyun Hu,
• Ozan S. Kumru,
• Mary Kate Morris,
• Jane Fontenot,
• Lisa Shirreff,
• Jonathan Do,
• Ya-Chen Cheng,
• Gayathri Vasudevan,
• Mark B. Feinberg,
• Francois J. Villinger,
• Carl Hanson,
• Sangeeta B. Joshi,
• David B. Volkin,
• Bali Pulendran,
• Peter S. Kim

Affiliations

Payton A.-B. Weidenbacher

Sarafan ChEM-H, Stanford University

Mrinmoy Sanyal

Sarafan ChEM-H, Stanford University

Natalia Friedland

Sarafan ChEM-H, Stanford University

Shaogeng Tang

Sarafan ChEM-H, Stanford University

Prabhu S. Arunachalam

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine

Mengyun Hu

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine

Ozan S. Kumru

Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas

Mary Kate Morris

California Department of Public Health

Jane Fontenot

New Iberia Research Center, University of Louisiana at Lafayette

Lisa Shirreff

New Iberia Research Center, University of Louisiana at Lafayette

Jonathan Do

Sarafan ChEM-H, Stanford University

Ya-Chen Cheng

Sarafan ChEM-H, Stanford University

Gayathri Vasudevan

IAVI

Mark B. Feinberg

IAVI

Francois J. Villinger

New Iberia Research Center, University of Louisiana at Lafayette

Carl Hanson

California Department of Public Health

Sangeeta B. Joshi

Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas

David B. Volkin

Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas

Bali Pulendran

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine

Peter S. Kim

Sarafan ChEM-H, Stanford University